An AMPK activator containing 1,1-diethoxyethane as an effective ingredient and use thereof
1,1-Diethoxyethane addresses the shortcomings of existing AMPK activators by activating AMPK and Akt, effectively improving obesity and insulin resistance, promoting the treatment and prevention of metabolic diseases, and possessing anti-aging and vitality-enhancing effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- 露科思阿尼玛有限公司
- Filing Date
- 2025-12-09
- Publication Date
- 2026-06-09
AI Technical Summary
Current technologies lack effective AMPK activators, making it impossible to effectively prevent or treat obesity, insulin resistance, and related metabolic diseases. Furthermore, existing drugs have limitations in improving metabolic syndrome.
Using 1,1-diethoxyethane (1,1-DEE) as the active ingredient, it activates AMPK and Akt by phosphorylating the Ser172 site of AMPK and oxidatively inactivating PTEN, thereby promoting fatty acid oxidation, glycolysis and mitochondrial biosynthesis, improving insulin sensitivity, and inhibiting obesity and metabolic diseases.
It achieves acute and long-term activation of AMPK, improves insulin sensitivity, alleviates symptoms of obesity and metabolic diseases, and provides anti-aging and vitality-enhancing effects.
Smart Images
Figure CN122163583A_ABST
Abstract
Claims
1. An AMPK (AMP-activated protein kinase) activator containing 1,1-diethoxyethane (1,1-DEE) as the active ingredient.
2. The AMPK activator according to claim 1, characterized in that, The 1,1-diethoxyethane promotes fatty acid oxidation or inhibits fatty acid production by inducing phosphorylation of Ser172 residues of AMPK, and promotes glucose breakdown or inhibits glycogen synthesis by regulating glycolysis.
3. The AMPK activator according to claim 1, characterized in that, The 1,1-diethoxyethane temporarily inhibits oxidative phosphorylation (OXPHOS) and mediates the generation of ROS (reactive oxygen species), thereby activating AMPK.
4. The AMPK activator according to claim 1, characterized in that, The 1,1-diethoxyethane promotes the biosynthesis of ATP, the biological energy source.
5. The AMPK activator according to claim 1, characterized in that, The 1,1-diethoxyethane promotes mitochondrial biosynthesis by increasing the expression of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1 alpha).
6. A pharmaceutical composition for the prevention or treatment of diseases requiring activation of AMPK (AMP-activated protein kinase), containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient, characterized in that, The diseases requiring AMPK activation include any one or more of the following: nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, dyslipidemia, atherosclerosis, hypertension, ischemic heart disease, inflammatory bowel disease, and rheumatoid arthritis.
7. An anti-aging cosmetic composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient.
8. A food composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient for the prevention or improvement of diseases requiring activation of AMPK (AMP-activated protein kinase), anti-aging, life extension or enhancement of physical vitality.
9. A feed composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient for the prevention or improvement of diseases requiring activation of AMPK (AMP-activated protein kinase), anti-aging, life extension or enhancement of physical vitality.
10. A composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient for improving insulin sensitivity or improving insulin resistance.
11. The composition for improving insulin sensitivity or reducing insulin resistance according to claim 10, characterized in that, The 1,1-diethoxyethane induces oxidative deactivation of PTEN by forming a disulfide bond between Cys124 and Cys71 residues of PTEN.
12. The composition for improving insulin sensitivity or reducing insulin resistance according to claim 10, characterized in that, The 1,1-diethoxyethane activates Akt by increasing phosphorylation at the Ser473 and Thr308 sites.
13. The composition for improving insulin sensitivity or reducing insulin resistance according to claim 10, characterized in that, The 1,1-diethoxyethane promotes glycolysis by increasing phosphorylation of the Ser483 residue of PFKFB2 (6-phosphofructo-2-kinase / fructose-2,6-biphosphatase 2).
14. A pharmaceutical composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient for the prevention or treatment of diseases associated with insulin resistance, characterized in that, The insulin resistance-related diseases include any one or more of the following: glucose regulation disorders, including type 1 diabetes, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), hyperglycemia, postprandial hyperglycemia, polycystic ovary syndrome (PCOS), hyperlipidemia, fasting plasma glucose (FPG), and postprandial plasma glucose.PPG) and / or glycated hemoglobin HbA1c and improving glycemic regulation; diabetes progression-related disorders, including prevention, delay, postponement, or reversal of progression from impaired glucose tolerance (IGT), impaired fasting glucose (IFG), insulin resistance, or metabolic syndrome to type 2 diabetes; diabetes complications, including cataracts, microvascular and macrovascular diseases, nephropathy, retinopathy, neuropathy, tissue ischemia, diabetic foot, acute coronary syndrome, peripheral artery occlusive disease, cardiomyopathy, and vasculature restenosis; weight management disorders, including weight loss, prevention of weight gain, or promotion of weight loss. Pancreatic β-cell-related disorders, including prevention, delay, postponement, or treatment of pancreatic β-cell degeneration and / or β-cell dysfunction, improvement and / or restoration of pancreatic β-cell function, and / or restoration of pancreatic insulin secretion function; insulin-related disorders, including maintaining and / or improving insulin sensitivity, prevention or treatment of hyperinsulinemia and / or insulin resistance.
15. A cosmetic composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient for the prevention or improvement of insulin resistance-related diseases.
16. A food composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient for the prevention or improvement of insulin resistance-related diseases.
17. A feed composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient for the prevention or improvement of insulin resistance-related diseases.
18. A pharmaceutical composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient for the prevention or treatment of obesity or obesity-related diseases.
19. A cosmetic composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient for the prevention or improvement of obesity or obesity-related diseases.
20. A food composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient for the prevention or improvement of obesity or obesity-related diseases.
21. A feed composition containing 1,1-diethoxyethane (1,1-DEE) as an active ingredient for the prevention or improvement of obesity or obesity-related diseases.